Abstract：
OBJECTIVE: The Multinational Association of Supportive Care in Cancer (MASCC)/European Society of Medical Oncology (ESMO) Patient Antiemetic Guideline Committee aimed to (1) adapt the updated evidence-based, clinical guidelines to patient-centered antiemetic guidelines and (2) develop patient education materials and statements.
METHODS: The MASCC 2023 Patient Antiemetic Guidelines were created and reviewed by antiemetic experts and patient advocates by incorporating the 2023 MASCC/ESMO antiemetic guidelines into patient-friendly language. Patient Education Statements were developed based on current literature and by utilizing an expert modified Delphi consensus (≥ 75% agreement). Patient advocate/focus group input and patient survey results were further integrated into Patient-Centered Antiemetic Guidelines and Education Statements.
RESULTS: Patient-Centered Antiemetic Guidelines were created using patient-friendly language and visual slides. Patient-friendly language was also utilized to communicate the Educational Statements. Key content categories identified for the Educational Statements included the following: nausea/vomiting definitions, causes, risk factors, categories, complications, accompanying symptoms, prophylactic antiemetic treatment, general management, when to call/what to ask the healthcare team, what caregivers can do, and available resources. All identified content met the ≥ 75% expert agreement threshold. Fifteen (15) items demonstrated 100% agreement, 11 items achieved ≥ 90% agreement, and three content items demonstrated 80 ~ 82% agreement.
CONCLUSIONS: The inaugural MASCC 2023 Patient Antiemetic Guidelines can help patients and caregivers understand the prevention of nausea and vomiting related to their cancer treatment. Educational Statements provide further patient information. Educating patients on how to utilize guideline antiemetics and the education statements can contribute improvements in the control of anticancer treatment-related nausea and vomiting.
METHODS: The MASCC 2023 Patient Antiemetic Guidelines were created and reviewed by antiemetic experts and patient advocates by incorporating the 2023 MASCC/ESMO antiemetic guidelines into patient-friendly language. Patient Education Statements were developed based on current literature and by utilizing an expert modified Delphi consensus (≥ 75% agreement). Patient advocate/focus group input and patient survey results were further integrated into Patient-Centered Antiemetic Guidelines and Education Statements.
RESULTS: Patient-Centered Antiemetic Guidelines were created using patient-friendly language and visual slides. Patient-friendly language was also utilized to communicate the Educational Statements. Key content categories identified for the Educational Statements included the following: nausea/vomiting definitions, causes, risk factors, categories, complications, accompanying symptoms, prophylactic antiemetic treatment, general management, when to call/what to ask the healthcare team, what caregivers can do, and available resources. All identified content met the ≥ 75% expert agreement threshold. Fifteen (15) items demonstrated 100% agreement, 11 items achieved ≥ 90% agreement, and three content items demonstrated 80 ~ 82% agreement.
CONCLUSIONS: The inaugural MASCC 2023 Patient Antiemetic Guidelines can help patients and caregivers understand the prevention of nausea and vomiting related to their cancer treatment. Educational Statements provide further patient information. Educating patients on how to utilize guideline antiemetics and the education statements can contribute improvements in the control of anticancer treatment-related nausea and vomiting.
摘要：
目的：多国癌症支持护理协会（MASCC）/欧洲肿瘤医学学会（ESMO）患者止吐指南委员会旨在（1）适应最新的循证，临床指南以患者为中心的止吐指南和（2）制定患者教育材料和声明。
方法：止吐专家和患者倡导者通过将2023年MASCC/ESMO止吐指南纳入患者友好的语言来创建和审查MASCC2023年患者止吐指南。根据现有文献并利用专家修改的Delphi共识（≥75％的一致性）制定患者教育声明。患者倡导者/焦点小组的输入和患者调查结果进一步纳入以患者为中心的止吐指南和教育声明。
结果：使用患者友好的语言和视觉幻灯片创建以患者为中心的止吐指南。还利用对患者友好的语言来传达教育声明。教育声明确定的主要内容类别包括：恶心/呕吐定义，原因,危险因素，类别,并发症,伴随症状,预防性止吐治疗,一般管理，什么时候打电话/问医疗团队什么，护理人员能做什么，和可用的资源。所有确定的内容都符合≥75%的专家协议阈值。十五（15）项表现出100％的协议，11项达成≥90%协议，三个内容项表现出80~82%的一致性。
结论：首届MASCC2023患者止吐指南可以帮助患者和护理人员了解与癌症治疗相关的恶心和呕吐的预防。教育声明提供进一步的患者信息。教育患者如何使用指南止吐药和教育声明可以改善抗癌治疗相关的恶心和呕吐的控制。
方法：止吐专家和患者倡导者通过将2023年MASCC/ESMO止吐指南纳入患者友好的语言来创建和审查MASCC2023年患者止吐指南。根据现有文献并利用专家修改的Delphi共识（≥75％的一致性）制定患者教育声明。患者倡导者/焦点小组的输入和患者调查结果进一步纳入以患者为中心的止吐指南和教育声明。
结果：使用患者友好的语言和视觉幻灯片创建以患者为中心的止吐指南。还利用对患者友好的语言来传达教育声明。教育声明确定的主要内容类别包括：恶心/呕吐定义，原因,危险因素，类别,并发症,伴随症状,预防性止吐治疗,一般管理，什么时候打电话/问医疗团队什么，护理人员能做什么，和可用的资源。所有确定的内容都符合≥75%的专家协议阈值。十五（15）项表现出100％的协议，11项达成≥90%协议，三个内容项表现出80~82%的一致性。
结论：首届MASCC2023患者止吐指南可以帮助患者和护理人员了解与癌症治疗相关的恶心和呕吐的预防。教育声明提供进一步的患者信息。教育患者如何使用指南止吐药和教育声明可以改善抗癌治疗相关的恶心和呕吐的控制。
